Barr R, Green CA, Sande CJ, Drysdale SB. Respiratory syncytial virus: diagnosis, prevention and management. Ther Adv Infect Dis. 2019;6:2049936119865798.
Openshaw PJM, Chiu C, Culley FJ, Johansson C. Protective and harmful immunity to RSV infection. Annu Rev Immunol. 2017;35:501–32.
Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–6.
Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–1502.
Lively JY, Curns AT, Weinberg GA, Edwards KM, Staat MA, Prill MM, et al. Respiratory Syncytial Virus-Associated Outpatient visits among children younger than 24 months. J Pediatr Infect Dis Soc. 2019;8(3):284–6.
Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98.
Sanchez-Luna M, Elola FJ, Fernandez-Perez C, Bernal JL, Lopez-Pineda A. Trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004–2012. Curr Med Res Opin. 2016;32(4):693–8.
Ministerio de Sanidad. Consumo y Bienestar Social. Registro de Actividad de Atención Especializada – RAE-CMBD. 2021. https://www.sanidad.gob.es/estadEstudios/estadisticas/cmbdhome.htm. Accessed 09 March 2022.
Muñoz-Quiles C, López-Lacort M, Úbeda-Sansano I, Alemán-Sánchez S, Pérez-Vilar S, Puig-Barberà J, Díez-Domingo J. Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain. Pediatr Infect Dis J. 2016;35(3):275–80.
Heppe Montero M, Gil-Prieto R, Walter S, Aleixandre Blanquer F, Gil De Miguel A. Burden of severe bronchiolitis in children up to 2 years of age in Spain from 2012 to 2017. Hum Vaccin Immunother. 2022;18(1):1883379.
Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341–53.
Viguria N, Martinez-Baz I, Moreno-Galarraga L, Sierrasesumaga L, Salcedo B, Castilla J. Respiratory syncytial virus hospitalization in children in northern Spain. PLoS ONE. 2018;13(11):e0206474.
World Health Organization. WHO preferred product characteristics of monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease. 2021. https://www.who.int/publications-detail-redirect/9789240021853. Accessed 24 August 2021.
Reina J, Iglesias C. Nirsevimab: Hacia La inmunización Universal De La población infantil frente al virus respiratorio sincitial. Vacunas. 2023;24(1):68–73.
Sanchez-Luna M, Burgos-Pol R, Oyaguez I, Figueras-Aloy J, Sanchez-Solis M, Martinon-Torres F, Carbonell-Estrany X. Cost-utility analysis of Palivizumab for respiratory syncytial virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis. 2017;17(1):687.
Reeves RM, van Wijhe M, Lehtonen T, Stona L, Teirlinck AC, Vazquez Fernandez L, et al. A systematic review of European clinical practice guidelines for respiratory Syncytial Virus Prophylaxis. J Infect Dis. 2022;226(Suppl 1):S110–6.
Flores-Gonzalez JC, Mayordomo-Colunga J, Jordan I, Miras-Veiga A, Montero-Valladares C, Olmedilla-Jodar M, et al. Prospective Multicentre Study on the epidemiology and current therapeutic management of severe bronchiolitis in Spain. Biomed Res Int. 2017;2017:2565397.
European Medicines Agency, Beyfortus. EPAR – Product Information. Annex 1: Summary of Product Charateristics. 2022. https://www.ema.europa.eu/en/documents/product-information/beyfortus-epar-product-information_en.pdf. Accessed 15 June 2023.
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for Prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837–46.
Wilkins D, Yuan Y, Chang Y, Aksyuk AA, Núñez BS, Wählby-Hamrén U, et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat Med. 2023;29(5):1172–9.
Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose Nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–25.
Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, et al. Nirsevimab for Prevention of RSV in term and late-preterm infants. N Engl J Med. 2023;388(16):1533–4.
Carbonell-Estrany X, Lázaro y de Mercado P. Health economics and RSV. Paediatr Respir Rev. 2009;10(Suppl 1):12–3.
Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010;11(1):105–15.
Schmidt R, Majer I, García Román N, Rivas Basterra A, Grubb E, Medrano López C. Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain. Health Econ Rev. 2017;7(1):47.
Kieffer A, Beuvelet M, Sardesai A, Musci R, Milev S, Roiz J, Lee JKH. Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model. J Infect Dis. 2022;226(Suppl 2):S282–92.
eSalud B, Consulting O. S.L. 2007. 2023. http://www.oblikue.com/bddcostes/. Accessed 15 June 2023.
Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo O, et al. Respiratory Syncytial Virus Seasonality: A Global Overview. J Infect Dis. 2018;217(9):1356–64.
Servia-Dopazo M, Purriños-Hermida MJ, Pérez S, García J, Malvar-Pintos A. [Usefulness of the microbiological surveillance of respiratory syncytial virus in Galicia (Spain): 2008–2017]. Gac Sanit. 2020;34(5):474–9.
Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022;22(1):759.
López-Bastida J, Oliva J, Antonanzas F, Garcia-Altes A, Gisbert R, Mar J, Puig-Junoy J. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11(5):513–20.
Carbonell-Estrany X, Figueras-Aloy J. Prevención De La infección Por virus respiratorio sincitial (VRS). Protocolos Diagnóstico Terapeúticos De La AEP: Neonatología Actualizado en. In.; 2008.
Sanchez Luna M, Pérez Muñuzuri A, Leante Castellanos JL, Ruiz Campillo CW, Sanz López E, Benavente Fernández I, et al. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants]. Pediatr (Engl Ed). 2019;91(5):348–50.
Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, et al. Safety of Nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386(9):892–4.
Simoes EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabanas F, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180–9.
Instituto Nacional de Estadística. Birth and Fertility, Birth-rate Indicators, National results. 2021. https://www.ine.es/en/. Accessed 24 Feb 2022.
Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, Buda S. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):630–7.
Hervás D, Reina J, Yañez A, del Valle JM, Figuerola J, Hervás JA. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis. 2012;31(8):1975–81.
Ministerio de Sanidad. Coberturas de primovacunación y dosis de recuerdo con vacuna hexavalente. Comunidades autónomas, año 2020. 2020. https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/coberturas/docs/Tabla5.pdf. Accessed 23 Mar 2022.
Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. PharmacoEconomics. 2004;22(5):275–84.
Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics. 2007;119(4):684–97.
Catalunya Health Department. Recomanacions d’ús de palivizumab per a la prevenció de les hospitalitzacions per infecció greu per virus sincític respiratori 2012.
MedImmune. Palivizumab Summary of Product Characteristics. 3 December 2019.
Moreno-Perez D, Calvo C. Epidemiological and clinical data of hospitalizations associated with respiratory syncytial virus infection in children under 5 years of age in Spain: FIVE multicenter study. Influenza Other Respir Viruses. 2014;8(2):209–16.
Instituto Nacional de Estadística. Encuesta de poblacion activa. EPA. Cuarto trimestre 2021. 2021. https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736176918&menu=ultiDatos&idp=1254735976595. Accessed 06 Apr 2022.
Instituto Nacional de Estadística. Salario por hora por tipo de jornada y periodo. 2021. https://www.ine.es/jaxiT3/Datos.htm?t=10885. Accessed 06 Apr 2022.
de Lázaro P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, Fitch Warner K. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32–35 weeks in Spain]. An Pediatr (Barc). 2006;65(4):316–324.
Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, Gallardo-Pino C, Gil-de-Miguel A. Respiratory Syncytial Virus Bronchiolitis in Children up to 5 years of age in Spain: Epidemiology and comorbidities: an observational study. Med (Baltim). 2015;94(21):e831.
Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós MT et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024.
Wilkins D, Yuan Y, Aksyuk A, Abram M, Leach A, Villafana T, Esser M. Nirsevimab for the prevention of respiratory syncytial virus infection: neutralising antibody levels following a single dose. Abstract #905 presented at European Society for Paediatric Infectious Diseases (ESPID) Athens, Greece, 9–13 May 2022. 2022. https://keneswp.azureedge.net/wp-content/uploads/sites/162/2022/05/ESPID22-Abstracts-Book.pdf. Accessed.
Demont C, Petrica N, Bardoulat I, Duret S, Watier L, Chosidow A, et al. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis. 2021;21(1):730.
Reeves RM, Hardelid P, Panagiotopoulos N, Minaji M, Warburton F, Pebody R. Burden of hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: a data linkage modelling study. J Infect. 2019;78:468–75.
Rainisch G, Adhikari B, Meltzer MI, Langley G. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. Vaccine. 2020;38(2):251–7.
Hodgson D, Pebody R, Panovska-Griffiths J, Baguelin M, Atkins KE. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis. BMC Med. 2020;18(1):348.
Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2(8):e367–74.
Li X, Bilcke J, Vázquez Fernández L, Bont L, Willem L, Wisløff T et al. Cost-effectiveness of respiratory Syncytial Virus Disease Prevention Strategies: maternal vaccine Versus Seasonal or Year-Round monoclonal antibody program in Norwegian children. J Infect Dis. 2022.
Zhou Y, Tong L, Li M, Wang Y, Li L, Yang D, et al. Recurrent wheezing and Asthma after respiratory Syncytial Virus Bronchiolitis. Front Pediatr. 2021;9:649003.
Drysdale SB. A Phase 3 randomized open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory syncytial virus (RSV) in infants (HARMONIE) [Oral presentation]. ESPID. 2023: Lisbon, Portugal. 2023.
Add Comment